These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8966571)

  • 1. Filling in the blanks in the p53 protein structure.
    Pennisi E
    Science; 1996 Nov; 274(5289):921-2. PubMed ID: 8966571
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a beta-hairpin to mimic an alpha-helix: cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction.
    Fasan R; Dias RL; Moehle K; Zerbe O; Vrijbloed JW; Obrecht D; Robinson JA
    Angew Chem Int Ed Engl; 2004 Apr; 43(16):2109-12. PubMed ID: 15083458
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.
    García-Echeverría C; Chène P; Blommers MJ; Furet P
    J Med Chem; 2000 Aug; 43(17):3205-8. PubMed ID: 10966738
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2.
    Gorina S; Pavletich NP
    Science; 1996 Nov; 274(5289):1001-5. PubMed ID: 8875926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
    McCoy MA; Gesell JJ; Senior MM; Wyss DF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
    Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
    Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA.
    Burch LR; Midgley CA; Currie RA; Lane DP; Hupp TR
    FEBS Lett; 2000 Apr; 472(1):93-8. PubMed ID: 10781812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer research. Drug candidate bolsters cell's tumor defenses.
    Marx J
    Science; 2004 Jan; 303(5654):23-5. PubMed ID: 14704399
    [No Abstract]   [Full Text] [Related]  

  • 11. The N-terminal domain of p53 is natively unfolded.
    Dawson R; Müller L; Dehner A; Klein C; Kessler H; Buchner J
    J Mol Biol; 2003 Oct; 332(5):1131-41. PubMed ID: 14499615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
    Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
    Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mini p53.
    Ferrier V
    Nat Cell Biol; 2002 Jun; 4(6):E156. PubMed ID: 12042832
    [No Abstract]   [Full Text] [Related]  

  • 15. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
    Bergamaschi D; Samuels Y; Zhong S; Lu X
    Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
    Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
    J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length.
    Lai Z; Auger KR; Manubay CM; Copeland RA
    Arch Biochem Biophys; 2000 Sep; 381(2):278-84. PubMed ID: 11032416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Rosal R; Pincus MR; Brandt-Rauf PW; Fine RL; Michl J; Wang H
    Biochemistry; 2004 Feb; 43(7):1854-61. PubMed ID: 14967026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a retroinverso p53 peptide as an inhibitor of MDM2.
    Sakurai K; Chung HS; Kahne D
    J Am Chem Soc; 2004 Dec; 126(50):16288-9. PubMed ID: 15600307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence-specific 1H, 15N, and 13C assignment of the N-terminal domain of the human oncoprotein MDM2 that binds to p53.
    Stoll R; Renner C; Mühlhahn P; Hansen S; Schumacher R; Hesse F; Kaluza B; Engh RA; Voelter W; Holak TA
    J Biomol NMR; 2000 May; 17(1):91-2. PubMed ID: 10909873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.